Fig 1: CFB expression and its association with clinical features. Association between CFB expression and (A) age, (B) sex, (C) smoking history, (D) residual tumor classification, (E) ECOG score, (F) Karnofsky performance score, (G) stage, (H) overall survival and (I) disease-free survival. Low-CFB, CFB expression <3.64; high-CFB, CFB expression =3.64. CFB, complement factor B; ECOG, Eastern Cooperative Oncology Group.
Fig 2: Identification of downregulated CFB expression in 3 paired lung adenocarcinoma samples. (A) Relative mRNA expression levels of CFB were decreased in tumor tissue as detected by reverse transcription-quantitative PCR (n=6). (B) Relative downregulated protein expression levels of CFB in lung adenocarcinoma samples as detected by western blotting (n=6). (C) CFB protein expression was decreased in tumor tissues compared with in matched adjacent non-tumor tissues. Both the relative mRNA and protein expression levels of CFB in each patient's lung tumor and adjacent non-tumor tissue were normalized against GAPDH values as determined in three replicate experiments. *P<0.05; **P<0.01; ****P<0.0001. C, lung adenocarcinoma tissue; P, matched adjacent non-tumor tissue; CFB, complement factor B.
Fig 3: Gene set enrichment analysis results of Kyoto Encyclopedia of Genes and Genomes pathways in three groups. A red box indicates that the pathway is upregulated and a blue box indicates that the pathway is downregulated. A yellow circle indicates that the pathway is significantly enriched. CFB, complement factor B.
Supplier Page from Abcam for Anti-Complement factor B antibody [EPR9288(B)]